Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Pipeline Update
Arcus Biosciences reported financial results for the third quarter ended September 30, 2026, and provided a pipeline update.
Story updates
09:07:54 PM UTC
SquawkNews
Arcus Biosciences reported financial results for the third quarter ended September 30, 2026, and provided a pipeline update. The release text provides no financial figures or prior-period comparisons.Material DetailsContext by AI AnalystThis is a quarterly update from a clinical-stage biotech, with…
09:10:16 PM UTC
SquawkNews
Arcus Biosciences 3Q Loss $128M >RCUS
09:10:16 PM UTC
SquawkNews
Arcus Biosciences 3Q Loss/Shr $1.00 >RCUS
09:13:22 PM UTC
SquawkNews
Nov 04 (Reuters) - Arcus Biosciences Q3 operating expenses USD 140 million.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today reported financial results for the third quarter ended September 30, 2026, and prov…